Region Midtjylland
- Address
- lock Available on a paid plan
Cardiovascular Disease Management in Type 1 Diabetes
The Endokrinologisk afd. at Region Midtjylland is evaluating how intensified care and novel therapies can lower heart risk in patients with type 1 diabetes. Trials assess ambitious treatment targets, the safety of finerenone, and overall cardiovascular outcomes.
- Intensified care protocols
- Risk assessment using MFI
- Finerenone safety and efficacy
- Impact on heart failure hospitalization
The effort involves four investigators and highlights the site’s commitment to advancing cardiovascular health in a hormonal disease context.
Preserving β‑Cell Function Through Vaccination
Researchers are testing whether influenza vaccination can help maintain β cell function in early‑stage type 1 diabetes. The purpose is to determine if immune protection translates into slower disease progression and better metabolic control.
- Early intervention strategies
- Immune modulation approaches
- Long‑term metabolic monitoring
- Patient quality of life assessment
Conducted at the Randers clinic, this study contributes to the broader hormonal disease research agenda.
Integrated Hormonal and Cardiovascular Research
The department merges expertise in hormonal diseases and cardiovascular diseases to address the dual challenges faced by individuals with type 1 diabetes. Focus areas include improving diagnostics and evaluating comprehensive care models that target both metabolic and heart health.
- Cross‑disciplinary care pathways
- Biomarker discovery initiatives
- Patient risk stratification methods
- Outcome measurement frameworks
As a non‑commercial hospital hub, the site plays a pivotal role in translating research into practical treatment improvements.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Karolinska Institutet1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Midtjylland
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Finerenone and Drug Combination in Reducing Cardiovascular Disease Risk in Type 1 Diabetes Patients at High Cardiovascular Risk | Steno Diabetes Center Copenhagen | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215) | 1 | Unknown | 2023-03-21 | 2023-03-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.